DDDivair Doneda

Divair Doneda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Divair Doneda has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Influence of tef flour and its association with other flours on the nutritional, technological, and sensory quality of bakery products

    by Raisa Vieira Homem, Divair Doneda, Tarso Ledur Kist, Janaína Guimarães Venzke, Vanuska Lima da Silva, Viviani Ruffo de Oliveira

    Summary: The objective of this study was to investigate chemical, technological, and sensory quality of tef in products made exclusively with tef flour and tef flour associated with other flours. The selection of the studies and the extraction of information were carried out through research in several databases. Tef flour was used in cakes, cookies, breads, cupcakes, muffins, and extruded snacks. Bread was the most evaluated product with tef flour associated with other flours or exclusively. Most of the outcomes were with tef (5–50%) associated with other flours. Increased levels of fibers, minerals, antioxidant capacity, and flavonoids were noted according to the percentage of tef. Technological characteristics demonstrated that these products showed intermediate final quality, due to the characteristics of volume, specific volume, firmness, and luminosity. Regarding sensory quality, studies that used (5–35%) tef flour associated with other flours were well‐accepted.


  • Physicochemical and Sensory Evaluation in Sautéed Caps and Stems of Edible Mushrooms

    by Ludymila Schulz Barroso, Cristiane Copetti, Marina Rocha Komeroski, Jéssica de Oliveira Saudades, Vanuska Lima da Silva, Divair Doneda, Liziane da Rosa Camargo, Simone Hickmann Flôres, Alessandro de Oliveira Rios, Viviani Ruffo de Oliveira

    Mushrooms are considered as a delicacy with high nutritional and sources of nutrients such as digestible proteins, carbohydrates, fiber and certain vitamins, as well as minerals and antioxidants. This study evaluates physicochemical and sensory quality of sautéed cap and stems of shimeji, brown Paris, white Paris and shiitake mushrooms. The values ranged on dry weight basis for: moisture: (80.99–89.44 g.100 g−1), ash (6.23–13.70 g.100 g−1), protein (14.57–37.81 g.100 g−1) and lipid (0.074–0.40 g.100 g−1). Shimeji and brown Paris caps presented high protein values and lipid content in was similar in mushrooms. Moisture and ash varied according to mushroom species, but white Paris mushroom presented the highest ash score in caps and stems. Shimeji caps and white Paris stems received the highest scores in sensory evaluation. This study highlighted the need to know nutritional parts and varieties of mushrooms.


  • Effect of whey protein addition on the nutritional, technological and sensory quality of banana cake

    by Liziane R. Camargo, Letícia M. Silva, Marina R. Komeroski, Tarso B. L. Kist, Carlos E. Rodrigues, Alessandro de O. Rios, Médelin M. Silva, Divair Doneda, Helena de O. Schmidt, Viviani R. Oliveira

    Summary: Whey proteins are of great nutritional and technological interest and their addition to bakery products can provide an increase in quality parameters such as texture, flavour and colour. In this study, four formulations were elaborated containing 0%, 10%, 20% and 30% of whey proteins. The physicochemical assessment included weight, height, volume, density, colour, hardness and centesimal and amino acid analysis. The sensory analysis included an affective test and buying intention. Height and volume after baking increased according to the amount of whey proteins added, while post‐baking density decreased. Whey protein added to cakes presented a protein increase higher than 50% when compared to the standard one. There was also a progressive increase in amino acids as quantities of whey proteins were added. The sensory showed a difference only in the 30% whey protein added cake, which proved to be less promising when compared to the other samples.


  • Open Access

    The prognostic value of the serum ferritin in a southern Brazilian cohort of patients with Gaucher disease

    by Tiago Koppe, Divair Doneda, Marina Siebert, Livia Paskulin, Matheus Camargo, Kristiane Michelin Tirelli, Filippo Vairo, Liane Daudt, Ida Vanessa D. Schwartz

    The clinical utility of serum ferritin as a biomarker of disease severity and prognosis in Gaucher disease (GD) is still debated. Here, we aimed to evaluate ferritin and its relation to clinicolaboratory parameters of GD patients seen at the Reference Center for Gaucher Disease of Rio Grande do Sul, Brazil, so as to gather evidence on the utility of ferritin as a biomarker of this condition. A retrospective chart review was performed collecting pre-and posttreatment data from GD patients. Eighteen patients with ferritin levels available before and after treatment were included in the study. Nine of these participants were males, and seventeen had type I GD. All patients were given either enzyme replacement (n = 16) or substrate reduction therapy (n = 2), and ferritin was found to decrease from 756 [318-1441] ng/mL at baseline to 521 [227-626] ng/mL (p=0.025) after 28.8 month soft treatment. Serum ferritin levels did not correlate with measures of disease severity, but showed an association with age at onset of treatment (ρ= 0.880; n = 18; p < 0.001). In conclusion, although serum ferritin did not correlate with disease severity, after a median 28.8 months of treatment, clinical outcomes had clearly improved, and ferritin levels had decreased.


  • Reply to Letter to the Editor – Leptin levels in Gaucher disease type I patients: A methodological approach

    by Divair Doneda, Andre L. Lopes, Bruno C. Teixeira, Suzana D. Mittelstadt, Cileide C. Moulin, Ida V.D. Schwartz

  • Ghrelin, leptin and adiponectin levels in Gaucher disease type I patients on enzyme replacement therapy

    by Divair Doneda, André L. Lopes, Bruno C. Teixeira, Suzana D. Mittelstadt, Cileide C. Moulin, Ida V.D. Schwartz


  • Assessment of Basal Metabolic Rate and Nutritional Status in Patients with Gaucher Disease Type III

    by Divair Doneda, Filippo P. Vairo, André L. Lopes, Álvaro Reischak-Oliveira, Pedro Schestatsky, Marino M. Bianchin, Cileide C. Moulin, Ida V. D. Schwartz

    Gaucher disease type III (GD III) is a rare form of GD characterized by neurological involvement and severe systemic disease. The objective of this study was to assess the nutritional status and energy metabolism of patients with GD III. Methods: The basal metabolic rate (BMR, measured by indirect calorimetry) and anthropometric parameters (height, weight, body mass index (BMI), and arm circumference) of three patients with GD III (p.L444P/L444P genotype) were assessed at different time points. The clinical severity of GD was assessed by means of physical examination, laboratory tests, imaging findings, and the severity scores proposed by Zimran (SSI) and Davies (SSNI). Results: The measured BMR of patients 1 (age 14 years, not on enzyme replacement therapy (ERT), SSI score 33, SSNI score 14.5), 2 (age 17 years, on ERT, SSI score 33, SSNI score 16), and 3 (age 20 years, on ERT, SSI score 33, SSNI score 7.5) was, respectively, 47%, 72%, and 15% higher than that estimated by the Harris–Benedict equation. Patients with a more severe phenotype had more marked hypermetabolism. Patients 1 and 2 had BMI-for-age z scores of −1.09 and −1.39, respectively, and height-for-age z scores of −4.27 and −3.02, respectively; patient 3 had a BMI of 24.7 kg/m2. Conclusion: All three patients showed hypermetabolism; however, the two patients with the highest BMR had more severe GD and were malnourished. Additional studies are warranted to assess whether hypermetabolism may be a biomarker of disease severity in GD.


  • Open Access

    Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review

    by Divair Doneda, Cristina B Netto, Cileide C Moulin, Ida Vanessa D Schwartz

    Background: Gaucher disease (GD) type I is the most common type of GD. Its main clinical manifestations are hepatosplenomegaly as well as bone and hematological abnormalities. The objective of the present study was to perform a literature review on the growth and metabolism of GD type I patients. Methods: We searched Pubmed and Scielo.br databases with predetermined study limits: case series (n≥5), clinical trials, systematic reviews, and meta-analyses, and enzyme replacement therapy (ERT) with alglucerase or imiglucerase. The outcomes of interest were the following: growth and development, weight, height, malnutrition, overweight, obesity, basal metabolism, hypermetabolism, insulin resistance, and diabetes. A total of 175 articles were found, of which 28 met the inclusion criteria; these articles were grouped into three central themes: 1) growth of children and adolescents before and after ERT; 2) metabolic changes that remained during ERT; and 3) changes in metabolic status resulting from the treatment. Results and discussion: The articles included in the present literature review are very heterogeneous, which hinders the analysis of data. They indicated that GD patients usually show low weight and height before ERT, which are improved with treatment in children and adolescents. Studies evaluating the energy metabolism by indirect calorimetry have indicated that the disease is associated with hypermetabolism. In adults, some changes in energy metabolism remain on ERT, and alterations, such as insulin resistance, seem to be associated with the treatment. It is not clear which are the required doses of imiglucerase for obtaining an adequate cost-effective relation, as well as the advisable therapeutic measures to avoid possible long-term adverse effects related to ERT. Conclusions: ERT tends to normalise the growth of children and adolescents with GD type I, it seems to cause a partial response in relation to some metabolic changes associated with the disease, and it can causes metabolic changes such as weight gain in adult patients. Therefore, additional research is necessary.


  • Enzyme Replacement Therapy in a Patient with Gaucher Disease Type III: A Paradigmatic Case Showing Severe Adverse Reactions Started a Long Time After the Beginning of Treatment

    by Filippo Vairo, Cristina Netto, Alicia Dorneles, Suzana Mittelstadt, Matheus Wilke, Divair Doneda, Kristiane Michelin, Camila Blos Ribeiro, Amanda Quevedo, Tatiane Vieira, et al.

    Introduction: There are three recombinant enzymes available for the treatment of Gaucher disease (GD): imiglucerase, velaglucerase alfa, and taliglucerase alfa. Case report: A male GD type III patient, 14 years old, genotype p.L444P/L444, diagnosed at 2 years old. He had been treated with imiglucerase for 9 years since the diagnosis. In 2008, however, he presented a severe adverse reaction to imiglucerase, characterized by cough, laryngeal stridor, and periorbital edema. The infusions were suspended for 3 months when imiglucerase was restarted with premedication and a slower infusion rate. After 5 months, he presented a new adverse reaction with vomiting, tachypnea, cough, and periorbital edema. Intradermal testing confirmed IgE-mediated reaction but serological tests were negative. After 2 years and 10 months with no specific treatment and a significant worsening of the clinical picture, taliglucerase alfa was prescribed, with premedication and a slower infusion rate. At the first infusion, he presented moderate adverse reaction and the infusions were suspended. After 2 months, velaglucerase alfa was initiated uneventfully. He maintains day-hospital infusions without premedication and shows improvement of clinical and laboratory parameters. Conclusion: This is the first report of the use of velaglucerase alfa in patients with GD type III. The use of recombinant enzymes is safe for the majority of GD patients, but severe reactions may occur even many years after the beginning of the treatment. Premedication and slower infusion rate reduce the incidence of adverse reactions but may not solve the problem. This case report further demonstrates the different safety profile among all the recombinant enzymes available for the treatment of GD.


  • Gaucher disease type I: Assessment of basal metabolic rate in patients from southern Brazil

    by Divair Doneda, André L. Lopes, Álvaro R. Oliveira, Cristina B. Netto, Cileide C. Moulin, Ida V.D. Schwartz